Related Experiment Video
Updated: Feb 11, 2026
08:32
Isolating Malignant and Non-Malignant B Cells from lck:eGFP Zebrafish
Published on: February 22, 2019
7.6K
Paraneoplastic glomerulopathies associated with hematologic malignancies
Jeyachandran Dhanapriya1, Thanigachalam Dineshkumar1, Ramanathan Sakthirajan1
1Institute of Nephrology, Madras Medical College and Rajiv Gandhi Government General Hospital, Chennai, Tamil Nadu, India.
Summary
Paraneoplastic glomerulopathy (PG) involves kidney damage from tumor cell products, not direct invasion. Early diagnosis and treating the underlying cancer are crucial for remission in patients with paraneoplastic nephrotic syndrome.
Area of Science:
- Nephrology
- Oncology
- Pathology
Background:
- Paraneoplastic glomerulopathy (PG) encompasses glomerular lesions indirectly caused by tumor cell products like cytokines and antigens.
- First described in 1922, PG is associated with various hematological malignancies.
- These kidney conditions can manifest before, during, or after cancer diagnosis and treatment.
Observation:
- Presents three cases of paraneoplastic nephrotic syndrome (NS) linked to hematological malignancies.
- Highlights the diverse timing of PG presentation relative to cancer diagnosis and disease status.
- Emphasizes that PG is not directly caused by tumor invasion or metastasis.
Findings:
- Paraneoplastic nephrotic syndrome can occur secondary to hematological malignancies.
- Tumor products, not direct tumor burden, are the causative agents in PG.
- Early identification and management of the neoplasia are key.
Implications:
- Prompt diagnosis and treatment of the underlying malignancy are essential for improving patient prognosis.
- Effective treatment of the neoplasia can lead to remission of paraneoplastic syndromes.
- Understanding the mechanisms of PG can guide therapeutic strategies for associated kidney diseases.
